US FDA Launches Pilot Program to Accelerate Drug Development and Clinical Trials
The US FDA has launched the Expedited IND Pilot program to accelerate clinical trial approvals, shortening the lengthy preparation process for new drug developments.
The US Food and Drug Administration (FDA) has launched a new pilot program designed to shorten the path from drug discovery in the laboratory to the initiation of its first human trials. According to the FDA, preparations for initial trials in the US can currently take up to two years, a timeframe that could delay medical developments even before their safety is tested in humans.
The program, called the Expedited IND Pilot, will connect drug-developing companies with research institutions possessing scientific and regulatory expertise. These institutions will assist companies in preparing the required applications to obtain approval to initiate clinical trials. In the first phase, eight to ten collaborations between companies and research institutions are expected to be selected.
Staged Review Instead of Waiting for All Documents
Currently, a company seeking to initiate its first human trial is required to submit an IND application to the FDA – a file that includes, among other things, data on the tested substance, the manufacturing process, findings from preclinical studies, and the proposed trial design. Under the pilot, the FDA will be able to review components of the application gradually, even before the entire file is completed. The goal is to identify scientific gaps, research design issues, or safety concerns in real-time, rather than waiting until all documents are submitted. The staged review may reduce the risk of the trial being halted during the official 30-day review period and allow companies to correct deficiencies during the preparation stages.
Early Coordination with Ethics Committees
The program will also encourage early coordination among the company, research institution, ethics committee, and trial sites. This will enable the parallel advancement of processes such as the selection of medical centers, approval of the research protocol, and preparation for participant recruitment. The objective is to minimize the time elapsed between the completion of the regulatory procedure and the recruitment of the first participant – a stage where additional delays can occur even after the FDA has allowed the trial to proceed.
What is Examined in the First Human Trial?
First-in-human trials are primarily designed to evaluate the safety of a substance: what side effects it may cause, its possible dosage range, and how it is absorbed, metabolized, and eliminated from the body. These trials are typically conducted in small groups of participants. Depending on the disease and the treatment being tested, participants may be healthy volunteers or patients dealing with a specific medical condition. Success in the initial stage does not prove that the drug is effective nor does it guarantee that it will reach the market. It is normally followed by larger, more extensive trials evaluating efficacy and safety in broader populations.
Acceleration is Not a Relaxation of Safety Requirements
The FDA emphasizes that the program is intended to streamline work with companies rather than reduce scientific or safety requirements. The agency will maintain its full regulatory authority, including the ability to request additional information, modify the trial design, or halt the trial if safety concerns arise for the participants. At this stage, this is a limited pilot rather than a sweeping overhaul of the US trial approval process. Its results will be used by the FDA to evaluate a permanent model, which may in the future recognize research institutions with proven capabilities in assisting drug development and preparing regulatory applications. For biomed companies and research institutions outside the US, including Israeli entities seeking to advance drugs in the American market, the success of the program could eventually impact timelines and working methods with the regulator.
